Finding the Best Sequencing Options for ADCs Across Breast Cancer Subtypes
Cross-resistance makes it important to determine sequencing options across antibody-drug conjugates for patients with breast cancer.
Navigating Treatment Decision-Making for CDK4/6 Inhibitors in Breast Cancer
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer
Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months, respectively, in patients with platinum-resistant ovarian cancer.
Frontline LDRT Plus Atezolizumab Combo Shows Efficacy in ES-SCLC
The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.
Developers Resubmit BLA for Tab-Cel in EBV+ Lymphoproliferative Disease
The FDA lifted a clinical hold on a new drug application for tabelecleucel as a treatment for EBV-positive lymphoproliferative disease in May 2025.
Immunotherapy, Novel Agents May Reshape the Early Breast Cancer Landscape
Heather McArthur, MD, focused on current and future strategies for treating early-stage breast cancer.
CDK4/6 Inhibitors Moving Into Early-Stage Breast Cancer is a “Huge Advance”
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Avutometinib/Defactinib Displays Safety, Efficacy in Ovarian Cancer Subtype
Among 115 patients treated with avutometinib and defactinib, only 5 deaths occurred in the study, none of which were related to study treatment.
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
Expanding Immunotherapy Use in Early-Stage Breast Cancer
In a discussion at IBC East, Heather McArthur, MD, highlighted how immunotherapy is being utilized for patients with early-stage breast cancer.
Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers
Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.
SRS Lessens Rate of Neurologic Death vs WBRT in SCLC and Brain Metastases
Results from a phase 2 study showed a median OS of 10.2 months in all patients with small cell lung cancer who received stereotactic radiation therapy.
Nivolumab Plus Relatlimab Shows Long-Term EFS Benefit in Advanced Melanoma
The B7-H3–low and TIGIT-high biosignatures correlated with superior event-free survival outcomes in those with melanoma treated with the combination.
Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC
According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma
A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.
Encorafenib Combo Earns Chinese Approval in BRAF V600E+ Metastatic CRC
Data from the phase 3 BEACON CRC trial support the approval of encorafenib plus cetuximab for this colorectal cancer population in China.
PFS Improves With TACE-Based Regimen in Unresectable Liver Cancer
Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
FDA Grants Orphan Drug Designation to Quemliclustat in Pancreatic Cancer
Quemliclustat plus gemcitabine and nab-paclitaxel chemotherapy outperformed median OS benchmarks in patients with metastatic PDAC.
FDA Clears AI-Based Visualization Software for Surgical Breast Cancer Care
Use of TumorSight Viz may support improved consistency, precision, and efficiency in breast cancer surgery.
The Evolving Landscape of CDK4/6 Inhibitors in Adjuvant HR+/HER2– Breast Cancer
Heather McArthur, MD, spoke about the use of CDK4/6 inhibitors in the adjuvant setting for patients with HR+/HER2– breast cancer.
Real-World Data Show Activity With Ivosidenib in IDH1+ Cholangiocarcinoma
Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
Characterizing Tumor Cell Diversity with AI
“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence
More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.
Tislelizumab/Chemotherapy Earns EU Approval in Nasopharyngeal Carcinoma
Data from the RATIONALE-309 trial support the European Commission’s approval of frontline tislelizumab plus chemotherapy in this patient population.
Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC
Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.
HTMC0435 Plus Chemotherapy Yields Responses in Relapsed ES-SCLC
HTMC0435 plus temozolomide led to an ORR of 24.5%, with a median OS of 12.0 months, in patients with platinum-sensitive and platinum-resistant small cell lung cancer.
